Literature DB >> 1449536

Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2',2'-difluorodeoxycytidine.

Y Z Xu1, W Plunkett.   

Abstract

Cellular metabolism studies had demonstrated previously that low cellular concentrations of 2',2'-difluorodeoxycytidine (dFdC) nucleotides are eliminated by deoxycytidylate deaminase (dCMPD), whereas dCMPD activity is inhibited at high cellular dFdC nucleotide levels (Heinemann et al., Cancer Res 52: 533-539, 1992). An assay for measuring dCMPD activity in intact human leukemia cells has now been developed to permit investigations of the interactions of dFdC nucleotides with dCMPD in intact cells in which the regulated nature of this enzyme was not disrupted. Using [14C]dCyd as the substrate, radioactivity that accumulated in dTTP was quantitated after high-pressure liquid chromotography by a radioactive flow detector. The assay was first characterized using either the dCMPD inhibitor tetrahydrodeoxyuridine (H4dUrd) which directly inhibits dCMPD, or thymidine and 5-fluoro-2'-deoxyuridine (FdUrd) which indirectly inhibit and activate dCMPD, respectively, by affecting the cellular dCTP:dTTP value. Measured by this in situ assay, there was a strong correlation between dCMPD activity and dCTP:dTTP levels. Consistent with previous studies using partially purified enzyme, incubation of cells with dFdC resulted in a concentration-dependent inhibition of dCMPD in situ. The mechanism of modulation of dCMPD by dFdC, however, was clearly different from that of thymidine and FdUrd. In addition to the effect of dFdC on cellular dCTP:dTTP, our findings also suggested an additional inhibitory mechanism, possibly a direct interaction between dCMPD and dFdC 5'-triphosphate. Thus, results obtained using this direct assay of dCMPD in intact cells support the hypothesis that dCMPD is inhibited by nucleotides of dFdC.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1449536     DOI: 10.1016/0006-2952(92)90077-v

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

1.  Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.

Authors:  Stephanie N Dorman; Katherina Baranova; Joan H M Knoll; Brad L Urquhart; Gabriella Mariani; Maria Luisa Carcangiu; Peter K Rogan
Journal:  Mol Oncol       Date:  2015-08-22       Impact factor: 6.603

Review 2.  Gemcitabine and radiosensitization in human tumor cells.

Authors:  D S Shewach; T S Lawrence
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

3.  Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.

Authors:  Ellen J B Derissen; Alwin D R Huitema; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2018-04-16       Impact factor: 4.335

Review 4.  New targets for pyrimidine antimetabolites for the treatment of solid tumours. 2: Deoxycytidine kinase.

Authors:  V W Ruiz van Haperen; G J Peters
Journal:  Pharm World Sci       Date:  1994-04-15

5.  Inhibition of ribonucleotide reductase by 2'-substituted deoxycytidine analogs: possible application in AIDS treatment.

Authors:  V Bianchi; S Borella; F Calderazzo; P Ferraro; L Chieco Bianchi; P Reichard
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

6.  Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine.

Authors:  Johan Vande Voorde; Suna Sabuncuoğlu; Sam Noppen; Anders Hofer; Farahnaz Ranjbarian; Steffen Fieuws; Jan Balzarini; Sandra Liekens
Journal:  J Biol Chem       Date:  2014-03-25       Impact factor: 5.157

7.  Algorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacy.

Authors:  Ozan Kahramanoğullari; Gianluca Fantaccini; Paola Lecca; Daniele Morpurgo; Corrado Priami
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

8.  Preclinical relevance of dosing time for the therapeutic index of gemcitabine-cisplatin.

Authors:  X M Li; K Tanaka; J Sun; E Filipski; L Kayitalire; C Focan; F Lévi
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

9.  Phase II study of gemcitabine in patients with advanced pancreatic cancer.

Authors:  J Carmichael; U Fink; R C Russell; M F Spittle; A L Harris; G Spiessi; J Blatter
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

10.  Dr Jekyll and Mr Hyde: a strange case of 5-ethynyl-2'-deoxyuridine and 5-ethynyl-2'-deoxycytidine.

Authors:  Anna Ligasová; Radek Liboska; David Friedecký; Kateřina Mičová; Tomáš Adam; Tomáš Oždian; Ivan Rosenberg; Karel Koberna
Journal:  Open Biol       Date:  2016-01       Impact factor: 6.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.